Standout Papers
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma (2017)
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study (2022)
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results (2012)
Immediate Impact
3 by Nobel laureates 28 from Science/Nature 94 standout
Citing Papers
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
2024 Standout
CAR-T cell manufacturing: Major process parameters and next-generation strategies
2024 Standout
Works of Lihua E. Budde being referenced
Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product
2020
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
2017 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Lihua E. Budde | 2861 | 1066 | 884 | 155 | 3.3k | |
| Brian G. Till | 2773 | 653 | 978 | 132 | 3.4k | |
| Jakub Svoboda | 2854 | 1601 | 693 | 183 | 3.6k | |
| Sunita D. Nasta | 3165 | 1630 | 956 | 177 | 4.5k | |
| Daniel J. Landsburg | 2302 | 875 | 703 | 135 | 3.2k | |
| Julio C. Chávez | 2250 | 1215 | 571 | 219 | 3.0k | |
| Tanya Siddiqi | 2380 | 1577 | 761 | 202 | 3.4k | |
| Caron A. Jacobson | 2484 | 1115 | 808 | 209 | 3.6k | |
| Matthew A. Lunning | 1929 | 1565 | 683 | 159 | 3.2k | |
| Craig S. Sauter | 3304 | 1130 | 947 | 186 | 4.5k | |
| Saad S. Kenderian | 1974 | 512 | 761 | 142 | 2.7k |
All Works
Login with ORCID to disown or claim papers
Loading papers...